Literature DB >> 9299966

ProC Global: the first functional screening assay for the complete protein C pathway.

F Dati1, G Hafner, H Erbes, W Prellwitz, M Kraus, F Niemann, M Noah, C Wagner.   

Abstract

In clinical practice, venous thromboembolic complications are much more frequent than bleeding disorders. In fact, disturbances within the protein C pathway due to coagulation factor V (FV) Leiden mutation and deficiency of protein C or protein S are the most frequent abnormalities in hereditary thrombophilia. Furthermore, acquired dysfunctions of the protein C system may predispose the single individual to an increased thrombotic risk. A routine-suited screening assay that would allow the monitoring of the proper interplay of factors in the protein C pathway could add an important factor to the basic coagulation profile. This consists of the prothrombin time and of the activated partial thromboplastin time, which currently allow only a screening for increased risk for bleeding but not for venous thromboembolism. A new functional screening test for the protein C system such as the presented ProC Global should therefore facilitate detection of FV Leiden as well as deficiency of protein C and protein S. The results of the present evaluation indicate that ProC Global is highly sensitive to activated protein C resistance/FV Leiden (100%) and protein C deficiency (90%) and sensitive to protein S deficiency (63%). Furthermore, the assay gives a quantitative measure of the net potential of the protein C pathway in relation to the intrinsic procoagulant system. The use of this assay for a prospective assessment of thromboembolic risk is the subject of current studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299966

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Thrombin generation, ProC(®)Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation.

Authors:  Thomas Thiele; Gregor Hron; Sarah Kellner; Christina Wasner; Antje Westphal; Theodore E Warkentin; Andreas Greinacher; Kathleen Selleng
Journal:  Blood Transfus       Date:  2015-07-09       Impact factor: 3.443

2.  Reduced protein C Global assay level in infertile women prior to IVF-ET treatment.

Authors:  Johnny S Younis; Moshe Ben-Ami; Ido Izhaki; Benjamin Brenner; Galit Sarig
Journal:  J Assist Reprod Genet       Date:  2013-11-06       Impact factor: 3.412

3.  Inhalation of a Short-Acting β2-Adrenoreceptor Agonist Induces a Hypercoagulable State in Healthy Subjects.

Authors:  Mais Ali-Saleh; Galit Sarig; Jacob N Ablin; Benjamin Brenner; Giris Jacob
Journal:  PLoS One       Date:  2016-07-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.